Great Novel Therapeutics Biotech & Medicals (TPEX:7427)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
39.65
-0.15 (-0.38%)
May 2, 2025, 2:00 PM CST
-30.44%
Market Cap 1.74B
Revenue (ttm) 1.69M
Net Income (ttm) -104.92M
Shares Out 43.64M
EPS (ttm) -2.55
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 40,388
Average Volume 97,721
Open 39.55
Previous Close 39.80
Day's Range 38.05 - 39.85
52-Week Range 30.30 - 56.20
Beta 0.01
RSI 49.56
Earnings Date May 14, 2025

About TPEX:7427

Great Novel Therapeutics Biotech & Medicals engages in the development of drugs for the treatment of advanced and refractory cancers. It develops drugs for cancer immunotherapy, including tumor microenvironment regulators, epigenetic immunoactivators, and immune-regulating multi-kinase inhibitors. The company was formerly known as GNT Biotech & Medicals Corporation. Great Novel Therapeutics Biotech & Medicals was founded in 2013 and is based in Taipei City, Taiwan. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2013
Employees 18
Stock Exchange Taipei Exchange
Ticker Symbol 7427
Full Company Profile

Financial Performance

In 2024, TPEX:7427's revenue was 1.69 million, a decrease of -65.26% compared to the previous year's 4.85 million. Losses were -104.92 million, 72.0% more than in 2023.

Financial Statements

News

There is no news available yet.